Why an aging population matters to healthcare supply chains

Senior population expected to double by 2050

The elderly are growing in numbers—fast. The United Nations projects the global population age 60 or older will double by 2050, reaching roughly 2.1 billion. Senior citizens already make up a significant part of the population in countries like the United States, Japan, and Germany, and other nations are following on their heels.

What it means for the medical device sector

• An increase in those with chronic diseases, mobility issues, and overall declining health expands demand for medical devices ranging from pacemakers to walkers.
• Age-related conditions such as cardiovascular disease, diabetes, and Alzheimer's are driving advancements in medical technologies. Advanced diagnostic and imaging equipment can aid in early detection of disease, inform treatments, and improve outcomes.
• The trend toward aging in place instead of institutional care is driving a growing need for home medical devices such as monitoring systems and wearable trackers.

What you can do right now

• Work with your logistics provider to build flexible, data‑driven supply chains and create efficiencies, as cost is increasingly seen as a competitive advantage.
• Prepare for rising shipping volumes by adopting real‑time item-level visibility tools and reinforcing security measures to protect high‑value, healthcare products.
• Strengthen secure, compliant device flows by leveraging programs like the Customs Trade Partnership Against Terrorism (CTPAT), which grants participants faster customs clearance.

Medicare cuts create headaches for medical device makers

Medicare reimbursement remains under pressure from U.S. budget mechanisms, including a 2% reduction for FY2026 as part of a process called sequestration. The Congressional Budget Office has also analyzed scenarios for additional Medicare payment reductions through 2034, though those reductions are potential and would occur only if Congress does not waive or offset them. PAYGO (short for pay-as-you-go) is a budget rule that triggers automatic spending cuts, including limits on Medicare payments, if new laws increase the federal deficit and Congress does not offset the cost.

Together, these reimbursement pressures can constrain provider cash flow, which may influence the pace at which hospitals and physicians invest in new technologies, clinical initiatives, and advanced equipment, and may also shape commercial dynamics for medical suppliers.

What you need to know

• Emerging therapies and medical equipment could be deprioritized if they are not adequately reimbursed. Medicare cuts could also increase the likelihood that hospitals and clinics will delay expansions and equipment upgrades.
• Biotech investors could become more cautious if reimbursements for new treatments are uncertain or declining.
• Major medical device manufacturers could experience negative stock impacts from proposed reimbursement reductions in adjacent care settings (e.g., home health) due to a perceived demand or margin risk.
• If reimbursement risks persist, the medical device industry could see an increase of mergers and acquisitions, with larger players purchasing smaller, innovative firms at discounted valuations.

How to get ready for what’s next

Medical device companies can manage through these uncertainties with good scenario planning and by optimizing their logistics operations.

Item-level visibility is no longer optional

Nearly 50% of life sciences companies cite lack of supply chain visibility and agility as their most pressing operational challenge. As regulatory enforcement tightens and product complexity increases, visibility is no longer a “nice to have” in healthcare supply chains. It’s becoming foundational to compliance, resilience, and patient safety.

What’s behind the trend

• Regulations such as the U.S. Drug Supply Chain Security Act (DSCSA) and global standards bodies such as GS1 demand data sharing and traceability.
• Product complexity is increasing rapidly, with the rise in sensitive, high-value biologics, specialty drugs, combination products, and advanced therapies.
• Healthcare networks are increasingly distributed, spanning outpatient clinics, ambulatory surgery centers, specialty pharmacies, home care, and everything in between.
• With the rise of digital platforms and AI analytics, stakeholders expect data to be timely, accurate, and actionable.

The logistics takeaway

Shippers must be able to prove product integrity, location, and condition at every handoff.

What you should do next

• Build item-level visibility as a key supply chain competency, along with sourcing, inventory strategy, regulatory compliance, and network design—not as a standalone initiative.
• Design supply chains around continuous visibility, with the ability to track product movement forward and backward at the unit level.
• Use real time, item-level data to support faster exception management, inventory management, and regulatory response.

U.S. Supreme Court strikes down some tariffs

The U.S. Supreme Court has ruled tariffs imposed under the International Emergency Economic Powers Act (IEEPA) were unlawful. The ruling brings those duties to an end but leaves key questions unresolved, most notably on potential refunds.

New tariffs under other legal authorities are widely expected. The administration has instituted a temporary 10% tariff under Section 122 of the 1974 Trade Act. This tariff is limited to 150 days unless an extension is granted by Congress. The administration has signaled it will replace it with permanent tariffs under Section 301.

Section 122 tariffs are added to other existing tariffs, but there are exceptions. Pharmaceuticals and active ingredients, as well as products that are currently subject to Section 232 tariffs are excluded. If only part of a product is subject to Section 232 (for instance because of steel or aluminum content), Section 122 may still apply to the non 232 portion.

Supply chain leaders should avoid making sourcing decisions based on the ruling and instead stay focused on proven resilience strategies, including diversifying sourcing and using trade programs where available. One important way to build resilience is by creating a sourcing hierarchy with suppliers from different countries and/or regions. The hierarchy should prioritize suppliers based on geopolitical realities, business continuity, and cost efficiency. A first step toward achieving this is dual sourcing: your current supplier plus a backup in a different country.

While focusing on proven resilience strategies is critical, there are ways to preserve your right to potential refunds:

• Review current customs entries, especially those nearing key deadlines.
• For closed (liquidated) entries, file a protest within 180 days of the liquidation date.
• For open entries, continue to monitor for a liquidation date to take appropriate action.
• Consider reaching out to a trade attorney to discuss if any legal filing should be made with the Court of International Trade.
• Use tools such as U.S. Tariff Impact Analysis, ACE Import Intelligence, and U.S. Customs Analytics to make informed decisions.

Table of Contents